Non-invasive estimation of liver fibrosis in non-alcoholic fatty liver disease using the 13C-caffeine breath test

Journal of Gastroenterology and Hepatology (Australia)

Volumn 26, Issue 9, 2011, Pages 1411-1416

  Park, Gordon J H ^a   Wiseman, Elke ^a   George, Jacob ^a   Katelaris, Peter H ^a   Seow, Francis ^a   Fung, Caroline ^a   Ngu, Meng C ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

CYP1A2; Quantitative; Steatohepatitis

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; FERRITIN; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; TRIACYLGLYCEROL;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CAFFEINE BREATH TEST; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FERRITIN BLOOD LEVEL; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN TISSUE; INTERNATIONAL NORMALIZED RATIO; LIVER BIOPSY; LIVER FIBROSIS; LIVER FUNCTION TEST; MALE; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; THROMBOCYTE; THROMBOCYTE COUNT; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 80052387485     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2011.06760.x     Document Type: Article

References (37)

1. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006; 43: S99-112.
2. Angulo P. Nonalcoholic fatty liver disease. N. Engl. J. Med. 2002; 346: 1221-31.
3. Hui JM, Kench JG, Chitturi S etal. Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology 2003; 38: 420-7.
4. Teli MR, James OF, Burt AD, Bennett MK, Day CP. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology 1995; 22: 1714-19.
5. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999; 30: 1356-62.
6. Adams LA, Lymp JF, St Sauver J etal. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005; 129: 113-21.
7. Adams LA, Sanderson S, Lindor KD, Angulo P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J. Hepatol. 2005; 42: 132-8.
8. Bonati M, Latini R, Galletti F, Young JF, Tognoni G, Garattini S. Caffeine disposition after oral doses. Clin. Pharmacol. Ther. 1982; 32: 98-106.
9. Blanchard J, Sawers SJ. The absolute bioavailability of caffeine in man. Eur. J. Clin. Pharmacol. 1983; 24: 93-8.
10. Arnaud MJ, Welsch C. Theophylline and caffeine metabolism in man. In: Rietbock N, Woodcock BG, Staib AH, eds. Theophylline and Other Methylxanthines. Braunschweig/Wiesbaden: Vieweg and Son, 1981; 135-48.
11. 13C-caffeine breath test as a noninvasive, quantitative test of liver function. Hepatology 2003; 38: 1227-36.
12. 13C-caffeine breath test distinguishes significant fibrosis in chronic hepatitis B and reflects response to lamivudine therapy. Aliment. Pharmacol. Ther. 2005; 22: 395-403.
13. 13C-caffeine breath test detects significant fibrosis in patients with nonalcoholic steatohepatitis. J. Clin. Gastroenterol. 2008; 42: 408-12.
14. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br. J. Surg. 1973; 60: 646-9.
15. Kleiner DE, Brunt EM, Van Natta M etal. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-21.
16. 2 breath tests as monitors of the cytochrome P450 dependent mixed function monooxygenase system. Prog. Clin. Biol. Res. 1983; 135: 119-45.
17. Preston T, McMillan DC. Rapid sample throughput for biomedical stable isotope tracer studies. Biomed. Environ. Mass Spectrom. 1988; 16: 229-35.
18. Craig H. Isotopic standards for carbon and oxygen and correction factors for mass-spectrometric analysis of carbon dioxide. Geochim. Cosmochim. Acta. 1957; 12: 133-49.
19. 13C-methionine breath test in patients with macrovesicular steatosis and patients with cirrhosis. Med. Sci. Monit. 2003; 9: CR6-11.
20. Portincasa P, Grattagliano I, Lauterburg BH, Palmieri VO, Palasciano G, Stellaard F. Liver breath tests non-invasively predict higher stages of non-alcoholic steatohepatitis. Clin. Sci. (Lond) 2006; 111: 135-43.
21. Guha IN, Parkes J, Roderick PR, Harris S, Rosenberg WM. Non-invasive markers associated with liver fibrosis in non-alcoholic fatty liver disease. Gut 2006; 55: 1650-60.
22. Wieckowska A, Feldstein AE. Diagnosis of nonalcoholic fatty liver disease: invasive versus noninvasive. Semin. Liver Dis. 2008; 28: 386-95.
23. Castera L, Pinzani M. Biopsy and non-invasive methods for the diagnosis of liver fibrosis: does it take two to tango? Gut 2010; 59: 861-6.
24. Angulo P, Hui JM, Marchesini G etal. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007; 45: 846-54.
25. Guha IN, Parkes J, Roderick P etal. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology 2008; 47: 455-60.
26. Wong VW, Vergniol J, Wong GL etal. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology 2010; 51: 454-62.
27. Castera L, Foucher J, Bernard P etal. Pitfalls of liver stiffness measurement: a 5-year prospective study of 13369 examinations. Hepatology 2010; 51: 828-35.
28. De Ledinghen V, Vergniol J, Foucher J, El-Hajbi F, Merrouche W, Rigalleau V. Feasibility of liver transient elastography with Fibroscan using a new probe for obese patients. Liver Int. 2010; 30: 1043-8.
29. Guengerich FP, Turvy CG. Comparison of levels of several human microsomal P-450 enzymes and epoxide hydrolase in normal and disease states using immunochemical analysis of surgical liver samples. J. Pharmacol. Exp. Ther. 1991; 256: 1189-94.
30. George J, Murray M, Karen B, Farrell GC. Differential alterations of cytochrome P450 proteins in livers from patients with severe chronic liver disease. Hepatology 1995; 21: 120-8.
31. Fiatarone JR, Coverdale SA, Batey RG, Farrell GC. Non-alcoholic steatohepatitis: impaired antipyrine metabolism and hypertriglyceridaemia may be clues to its pathogenesis. J. Gastroenterol. Hepatol. 1991; 6: 585-90.
32. Weltman MD, Farrell GC, Hall P, Ingelman-Sundberg M, Liddle C. Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology 1998; 27: 128-33.
33. Chalasani N, Gorski JC, Asghar MS etal. Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis. Hepatology 2003; 37: 544-50.
34. Emery MG, Fisher JM, Chien JY etal. CYP2E1 activity before and after weight loss in morbidly obese subjects with nonalcoholic fatty liver disease. Hepatology 2003; 38: 428-35.
35. Bedossa P, Dargerre D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003; 38: 1449-57.
36. Merriman RB, Ferrell LD, Patti MG etal. Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease. Hepatology 2006; 44: 874-80.
37. Rousselet MC, Michalak S, Dupre F etal. Sources of variability in histological scoring of chronic viral hepatitis. Hepatology 2005; 41: 257-64.